Palliative surgical bypass is superior to palliative endoscopic stenting in patients with malignant gastric outlet obstruction: systematic review and meta-analysis.
Endoscopic stenting
Malignant GOO
Meta-analysis
Surgical bypass
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
03
05
2019
accepted:
01
07
2019
pubmed:
25
7
2019
medline:
22
5
2020
entrez:
24
7
2019
Statut:
ppublish
Résumé
Gastrojejunostomy (GJ) and self-expanding metal stents (SEMS) are the two most common palliative treatment options for patients with malignant gastric outlet obstruction (GOO). Randomised trials and retrospective studies have shown discrepant results, so that there is still a controversy regarding the optimal treatment of GOO. Medline, Web of Science and Cochrane Library were systematically searched for studies comparing GJ to SEMS in patients with malignant GOO. Primary outcomes were survival and postoperative mortality. Secondary outcomes were frequency of re-interventions, major complications, time to oral intake and length of hospital stay. Twenty-seven studies, with a total of 2.354 patients, 1.306 (55.5%) patients in the SEMS and 1.048 (44.5%) patients in the GJ group, were considered suitable for inclusion. GJ was associated with significantly longer survival than SEMS (mean difference 43 days, CI 12.00, 73.70, p = 0.006). Postoperative mortality (OR 0.55, CI 0.27, 1.16, p = 0.12) and major complications (OR 0.73, CI 0.5, 1.06, p = 0.10) were similar in both groups. The frequency of re-interventions, however, was almost three times higher in the SEMS group (OR 2.95, CI: 1.70, 5.14, p < 0.001), whereas the mean time to oral intake and length of hospital stay were shorter in the SEMS group (mean differences - 5 days, CI - 6.75, - 3.05 days, p < 0.001 and - 10 days, CI - 11.6, - 7.9 days, p < 0.001, respectively). Patients with malignant GOO and acceptable performance status should be primarily considered for a palliative GJ rather than SEMS.
Sections du résumé
BACKGROUND
Gastrojejunostomy (GJ) and self-expanding metal stents (SEMS) are the two most common palliative treatment options for patients with malignant gastric outlet obstruction (GOO). Randomised trials and retrospective studies have shown discrepant results, so that there is still a controversy regarding the optimal treatment of GOO.
METHODS
Medline, Web of Science and Cochrane Library were systematically searched for studies comparing GJ to SEMS in patients with malignant GOO. Primary outcomes were survival and postoperative mortality. Secondary outcomes were frequency of re-interventions, major complications, time to oral intake and length of hospital stay.
RESULTS
Twenty-seven studies, with a total of 2.354 patients, 1.306 (55.5%) patients in the SEMS and 1.048 (44.5%) patients in the GJ group, were considered suitable for inclusion. GJ was associated with significantly longer survival than SEMS (mean difference 43 days, CI 12.00, 73.70, p = 0.006). Postoperative mortality (OR 0.55, CI 0.27, 1.16, p = 0.12) and major complications (OR 0.73, CI 0.5, 1.06, p = 0.10) were similar in both groups. The frequency of re-interventions, however, was almost three times higher in the SEMS group (OR 2.95, CI: 1.70, 5.14, p < 0.001), whereas the mean time to oral intake and length of hospital stay were shorter in the SEMS group (mean differences - 5 days, CI - 6.75, - 3.05 days, p < 0.001 and - 10 days, CI - 11.6, - 7.9 days, p < 0.001, respectively).
CONCLUSIONS
Patients with malignant GOO and acceptable performance status should be primarily considered for a palliative GJ rather than SEMS.
Identifiants
pubmed: 31332564
doi: 10.1007/s00464-019-06955-z
pii: 10.1007/s00464-019-06955-z
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3153-3164Références
Gastrointest Endosc. 2001 Mar;53(3):329-32
pubmed: 11231392
Radiology. 2001 Jun;219(3):679-83
pubmed: 11376254
Cardiovasc Intervent Radiol. 2001 May-Jun;24(3):147-53
pubmed: 11443401
Am J Gastroenterol. 2002 Jan;97(1):4-6
pubmed: 11808968
Surg Endosc. 2002 Feb;16(2):310-2
pubmed: 11967685
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Postgrad Med J. 1960 Dec;36:706-13
pubmed: 13742310
Endoscopy. 2004 Jan;36(1):73-8
pubmed: 14722859
Br J Surg. 2004 Feb;91(2):205-9
pubmed: 14760669
Anticancer Res. 2004 Jan-Feb;24(1):269-71
pubmed: 15015607
World J Surg. 2004 Aug;28(8):812-7
pubmed: 15457364
Radiographics. 2004 Nov-Dec;24(6):1561-73
pubmed: 15537965
Gastrointest Endosc. 2005 Mar;61(3):421-6
pubmed: 15758914
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
Gastrointest Endosc. 1992 Jan-Feb;38(1):1-6
pubmed: 1612364
J Gastroenterol. 2005 Oct;40(10):932-7
pubmed: 16261429
Surg Endosc. 2006 Feb;20(2):239-42
pubmed: 16362479
Surg Endosc. 2006 Jul;20(7):1083-7
pubmed: 16703436
J Surg Oncol. 2007 Oct 1;96(5):389-96
pubmed: 17474082
BMC Gastroenterol. 2007 Jun 08;7:18
pubmed: 17559659
Am J Surg. 2009 Jul;198(1):92-9
pubmed: 19482259
Surg Endosc. 2010 Feb;24(2):290-7
pubmed: 19551436
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Gastrointest Endosc. 2010 Mar;71(3):490-9
pubmed: 20003966
Scand J Gastroenterol. 2011 May;46(5):583-90
pubmed: 21366507
Gastrointest Endosc. 2011 Jul;74(1):13-21
pubmed: 21704805
Surg Endosc. 2012 Feb;26(2):323-9
pubmed: 21898024
Dig Liver Dis. 2012 Jan;44(1):37-43
pubmed: 21937292
Dig Endosc. 2012 Mar;24(2):71-8
pubmed: 22348830
Surg Endosc. 2012 Nov;26(11):3114-9
pubmed: 22549377
Surg Endosc. 2013 Jun;27(6):2068-75
pubmed: 23299137
Gastrointest Endosc. 2013 Jul;78(1):55-62
pubmed: 23522025
J Gastrointest Oncol. 2014 Apr;5(2):92-8
pubmed: 24772336
Gastrointest Endosc. 2015 Feb;81(2):321-32
pubmed: 25085332
Abdom Radiol (NY). 2016 Nov;41(11):2233-2240
pubmed: 27290721
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Surg Endosc. 2017 Oct;31(10):4217-4223
pubmed: 28281127
Pancreatology. 2017 Nov - Dec;17(6):983-989
pubmed: 29066391
Intern Med. 2018 Jun 1;57(11):1517-1521
pubmed: 29434131
Pancreatology. 2018 May 3;:null
pubmed: 29753623
Cochrane Database Syst Rev. 2018 May 30;5:CD012506
pubmed: 29845610
Am Surg. 2018 Jun 1;84(6):991-995
pubmed: 29981637
Clin Gastroenterol Hepatol. 2019 Jun;17(7):1295-1302.e1
pubmed: 30391433